Belumosudil mesylate is under clinical development by Kadmon and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Belumosudil mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Belumosudil mesylate overview

Belumosudil mesylate (Rezurock/ Rholistiq) is an immunosuppressant. It is formulated as film coated tablets and tablets for oral route of administration. Rezurock is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy and who have an inadequate response to corticosteroids. Belumosudil mesylate (KD-025, SLx-2119) is under development for the treatment of idiopathic pulmonary fibrosis, diffuse cutaneous systemic sclerosis and graft versus host disease. It is a small molecule administered through orally and parenteral route. It is a selective inhibitor of Rho kinase 2 (ROCK2). It is developed based on Pharmacomer Technology Platform. It was also under development for the treatment of atherosclerosis, Sjogren’s syndrome, NASH (Nonalcoholic steatohepatitis), inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, psoriatic arthritis, systemic sclerosis (scleroderma), psoriasis vulgaris, rheumatoid arthritis and lupus nephritis.

Kadmon overview

Kadmon is an integrated biopharmaceutical company that discovers, develops and markets small molecules and biologics for autoimmune and fibrotic diseases, various types of cancer, and genetic diseases. The company’s pipeline encompasses investigational candidates for the treatment of moderate to severe psoriasis, idiopathic pulmonary fibrosis, and polycystic kidney disease among others. Its pipeline candidates are based on its small molecule and biologics platforms. It also develops in-licensed product candidates and technologies. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline candidates. Kadmon is headquartered in New York, the US.

For a complete picture of Belumosudil mesylate’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.